UroLift植入物:快速持久缓解前列腺梗阻的机制
本研究通过犬组织学、UroLift系统治疗患者切除组织及制造商上市后监测数据,阐明UroLift植入物的长期生物学作用机制。结果显示植入物导致组织压迫,可能引起局灶性缺血,进而导致局部萎缩和轻微慢性炎症,最终重塑组织使前列腺尿道增宽。结论表明该装置对全身组织无影响,具有良性和生物相容性,并为临床观察到的持久性提供组织学解释。
要点
- UroLift植入物通过组织压迫导致局灶性缺血、局部萎缩和轻微炎症,重塑增宽尿道。
- 组织学证据支持UroLift系统良性且生物相容,对全身组织无影响。
- 该机制为临床观察到的快速持久缓解前列腺梗阻提供了组织学解释。
核心结论
- UroLift植入物通过组织压迫、局灶性缺血、局部萎缩和轻微慢性炎症重塑组织,增宽前列腺尿道,且对全身组织无影响。
研究设计与样本
- 研究利用犬组织学结果、UroLift系统治疗患者切除组织及制造商收集的上市后监测数据。
主要发现
- 植入物输送导致组织压迫,可能引起局灶性缺血,观察到局部萎缩和轻微慢性炎症。
- 组织重塑最终产生增宽的前列腺尿道。
- 装置对全身组织无影响,表明其良性和生物相容。
临床怎么用
- 组织学机制支持UroLift系统作为微创方法快速持久缓解前列腺梗阻。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Benign prostatic hyperplasia (BPH) is an affliction of the aging male population that contributes to bothersome and disruptive lower urinary tract symptoms (LUTS). The UroLift® implant has been developed as a mechanical means of widening the prostatic urethra and providing relief from lower urinary tract symptoms (LUTS) through a minimally invasive procedure. METHODS: In the current study, we utilize histological results from canine tissue, resected tissue from human subjects treated with the UroLift System and post-market surveillance data collected by the manufacturer in order to elucidate the long-term biological mechanism of action of the UroLift implant. RESULTS: The delivery of the implant causes tissue compression, likely resulting in focal ischemia that causes observed local atrophy and minimal-mild chronic inflammation that ultimately remodels tissue to produce a widened prostatic urethra. CONCLUSIONS: These studies reveal the lack of impact the device has on systemic tissue, providing evidence that the UroLift System is benign and biocompatible, and offering histologic explanation for the clinically observed durability.
引用
- Roehrborn CG, Chin PT, Woo HH, et al. The UroLift implant: mechanism behind rapid and durable relief from prostatic obstruction. Prostate Cancer Prostatic Dis. 2021. PMID: 34363010. doi:10.1038/s41391-021-00434-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。